Mitochon Pharmaceuticals is a start-up biotech company that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Our development programs are primarily focused on neurodegenerative diseases including: Huntington’s, Multiple Sclerosis, Epilepsy, Autism, Rett Syndrome, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.